A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Debamestrocel (Primary) ; Debamestrocel (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Sponsors Brainstorm Cell Therapeutics
- 10 May 2016 According to a BrainStorm Cell Therapeutics media release, combined results from this and a phase IIa trial (CTP 700228777) were presented at the ISRASTEM 2016 and 6th Israel Stem Cell Society (ISCS) joint annual meeting.
- 29 Mar 2016 According to a BrainStorm media release, combined results from this and a phase IIa trial (CTP 700228777) will be presented at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual Meeting
- 11 Jan 2016 Combined results of this and a phase IIa trial (CTP 700228777) published in the JAMA Neurology, according to a BrainStorm Cell Therapeutics media release.